La Jolla Pharmaceutical Shares Plunge Shares of La Jolla Pharmaceutical Co. plunged more than 50 percent Friday after the Food and Drug Administration told the drug developer it needs to conduct another study of its lead drug candidate, a lupus treatment called Riquent, prior to approval.